2月25日晚间，山西上市药企仟源医药发布公告称，公司与舟山荣豪贸易有限公司（以下简称"舟山荣豪"）联合参与浙江仟源海力生制药有限公司（以下 简称"仟源海力生"）40%股权司法拍卖，并最终以1.55亿元的价格竞得该笔股权。 仟源医药、舟山荣豪分别出资7736万元各自拿下20%股权。 根浙江省宁波市鄞州区人民法院的公告，海力生集团持有的仟源海力生40%股权于2月24日开始进行司法拍卖，标的评估价为1.77亿元，起拍价1.24亿元， 保证金2000万元。经历43次出价后，仟源医药与舟山荣豪联合体以1.55亿元的最高应价胜出。 仟源医药曾于2月24日召开的第六届董事会第二次会议审议通过相关议案，授权经营层以不超过8000万元的自有资金参与本次司法拍卖，实际出价在授权 范围内。 本次交易完成后，仟源医药持有仟源海力生80%股权，舟山荣豪持股20%。值得注意的是，二者本身就与仟源海力生渊源颇深。 值得注意的是，仟源医药原本就持有标的企业仟源海力生60%股权，此次股权交易完成后持股比例将进一步增至80%，从而进一步强化了控制权；而舟山 荣豪同样与仟源海力生渊源颇深。 仟源海力生的股权为何会走上司法程序？仟源医药、舟山荣豪看 ...

来源：医线Insight 春节刚过，又一家创新药企决定冲刺港交所。 2月25日，天辰生物医药（苏州）股份有限公司（简称"天辰生物"）递交招股书。 这家成立于2020年10月的创新药企，在短短5年时间里，不仅将核心管线一路推至临床III期，更在行业 公认的"资本寒冬"中逆势完成了7轮、累计5.215亿元的融资。 其中，在2025年5月完成的C轮融资中，天辰生物投后估值一举突破20亿元大关。 | 融资 | | | 融资金额 | 投资后估值 | | | --- | --- | --- | --- | --- | --- | | 轮次 | 协议签署日期 | 资金恐救结清日期 | (人民币) | (人民币) | 参与的投资方 | | A$8 | 2020年12月30日及 | | 9850 | | 上海安壮、OFC博晖基金、上海友宣 | | | 2021年6月20日 | 2021年7月29日 | 万元 | 3.985亿元 | 、石药仙瞳、永石汇金、东南投资、 | | | | | | | 安徽安元、仙疆顺创、新生华创 | | | 2022年5月23日 | 2025年4月1日 | 4000 | | 刘博士、湖州友宣(出资责任 ...

麓鹏制药董事长兼CEO谭芬来博士。 工作中的谭芬来博士。 在中国创新药发展版图中，创新药老兵谭芬来博士是一个独特的存在。 七年前，在由其主导临床研发的中国首个小分子靶向抗癌药埃克替尼(凯美纳)惠及数十万患者、首个 ALK靶点创新药恩沙替尼蓄势待发之时，他却选择卸下荣光，创立了一家连名字都直抒高远之志的创 新药企业——麓鹏制药。 七年后的今天，他带领团队交出了一份份令人满意的阶段性成绩单：全球首个且唯一共价兼非共价布鲁 顿酪氨酸激酶(BTK)抑制剂洛布替尼，成为中国首个被认定为弥漫大B细胞淋巴瘤(DLBCL)突破性疗法 的BTK抑制剂，并已启动关键性注册Ⅱ期临床研究；针对复发或难治性套细胞淋巴瘤(R/R MCL)的新药 上市申请(NDA)，获国家药品监督管理局药品审评中心(CDE)受理并纳入优先审评程序；启动治疗复发 或难治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(R/R CLL/SLL)的全球三期头对头临床试验，正面挑战国 际制药巨头礼来公司的第三代BTK抑制剂匹妥布替尼，直面全球化竞争。 从杭州西子湖畔到广州黄埔科学城，谭芬来完成的不只是一次地理上的回归，更是一场从"创中国首 个"到"创全球首个"的信念升级。在 ...

估值约20亿 股权方面，截至1月24日，Cumbre实体为丹诺医药的单一最大股东集团，可行使公司合共约18.82%投票 权。各Cumbre实体在Morton H Meyerson（"Meyerson"）于2025年8月去世前由Meyerson及其家族成员最 终拥有及控制。Cumbre实体将持续作为公司的被动投资者且不会参与公司的日常营运。自成立以来， 创始人、董事会主席、执行董事、首席执行官兼总经理马振坤及Cumbre实体均一致投票，且Cumbre实 体亦与马振坤在与公司有关的事宜表决中立场一致。马振坤连同ESOP平台控制公司约13.61%的投票 权。 近日，丹诺医药（苏州）股份有限公司（下称"丹诺医药"）向港交所递表，拟在主板上市，中信证券和 农银国际为其联合保荐人。 IPO日报注意到，丹诺医药近两年三季度累计亏损4.53亿元，王牌产品有望在2026年末获批上市，已进 入商业化冲刺阶段，最新估值约为20.13亿元。 产品获批在望 丹诺医药成立于2013年，是一家临近商业化阶段的生物科技公司，专注于发现、开发及商业化差异化的 创新药产品，以解决细菌感染及细菌代谢相关疾病领域的未被满足临床需求。截至1月24日， ...

Core Viewpoint - Changchun High-tech's stock price surged by 11.4% over two trading days, closing at 98.50 yuan per share, with a total market value of 40.18 billion yuan [1] Group 1: Clinical Trial Approval - Changchun High-tech's subsidiary, GenSci, received approval from the National Medical Products Administration for clinical trials of GenSci141 ointment, aimed at treating conditions related to hypogonadism and congenital adrenal hyperplasia in children [3] - The announcement highlighted that drug treatment is the primary method for addressing penile size issues in boys, with no approved medications for this indication until now [3] Group 2: Financial Performance - The company projected a significant decline in net profit for 2025, estimating between 150 million to 220 million yuan, representing a year-on-year decrease of 91.48% to 94.19% [4] - The fourth quarter is expected to show a massive loss of 945 million to 1.015 billion yuan, with a year-on-year increase in losses of 358.74% to 392.72% [5] - The decline in profit is attributed to pricing adjustments in the growth hormone business, ongoing losses from its subsidiary, and high costs associated with new product development [5] Group 3: Market Competition and Future Prospects - The growth hormone market has become increasingly competitive, necessitating Changchun High-tech to seek new revenue growth points [6] - The potential of GenSci141 ointment to drive revenue remains uncertain as it is still in the clinical trial phase [6] - The company has a rich pipeline of products and is focusing on new products with high market potential, such as Jin Peixin and Meishiya, which have shown promising sales figures [7]

本报讯(记者蒙婷婷)2月25日晚间，成都康弘药业（002773）集团股份有限公司(以下简称"康弘药业")发 布公告称，近日，公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意其自主研发 的KHN707片开展用于失眠症的临床试验。 公告显示，KHN707片是康弘药业自主研发的选择性食欲素2(OX2R)受体拮抗剂，属于化药1类创新药， 剂型为片剂。前期已完成的研究结果显示KHN707片安全性较好，且在失眠模型中具有良好的治疗作 用，预期临床应用前景较好。 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][6]. Core Insights - The report highlights the strong innovative research and development capabilities of the company, which is entering a harvest period for innovative drugs while establishing an international business development ecosystem with several significant collaborations [2][10]. - The company is expected to achieve a compound annual growth rate (CAGR) in earnings per share (EPS) of 48% from 2025 to 2027, with a target price set at HKD 16.58 [10]. Financial Summary - Total revenue is projected to be RMB 31,450.11 million in 2023, with a slight increase of 1.7% year-on-year. However, a decline of 7.8% is expected in 2024, followed by a gradual recovery in subsequent years [4][11]. - Gross profit is forecasted to be RMB 22,177 million in 2023, with net profit expected to be RMB 5,873 million, reflecting a decrease of 3.6% [4][11]. - The price-to-earnings (P/E) ratio is projected to be 18.26 in 2023, increasing to 24.78 in 2024 before declining to 16.80 in 2025 [4][11]. Pipeline Overview - The company has a leading position in the oncology pipeline, with SYS6010 being the fastest progressing EGFR ADC globally, and multiple early-stage assets expected to report data in 2026 [10][14]. - In the weight loss and metabolic fields, the company has established a leading position domestically, with a strategic collaboration with AstraZeneca to develop innovative long-acting peptide drugs [10][24]. - The company has secured a total deal value of USD 18.5 billion from collaborations, including upfront payments and potential milestone payments [10][24]. Clinical Development - The report outlines several key clinical trials, including SYS6010, which is in Phase III for EGFRm NSCLC, and various other assets in different stages of development [18][20]. - The company is actively recruiting for multiple trials, with significant data expected to be released in 2026 [18][20]. Market Position - The company is positioned as a leader in the domestic market for small nucleic acid technology, with a strong pipeline in siRNA [10][24]. - The report emphasizes the company's competitive edge in the next-generation weight loss drugs and cardiovascular metabolic therapies, supported by strategic partnerships with multinational corporations [10][24].

Investment Rating - The report assigns an "Accumulate" rating to the company [1][6]. Core Insights - The report highlights the strong innovation and R&D capabilities of the company, which is entering a harvest period for innovative drugs and has established an international business development ecosystem with several significant licensing agreements [2][10]. - The company is expected to achieve a significant increase in EPS from 0.37 in 2024 to 0.75 in 2025, with a projected growth rate of 48% [10]. - The target price for the company is set at 16.58 HKD, reflecting a favorable valuation based on comparable company analysis [10]. Financial Summary - Total revenue is projected to be 31,450.11 million RMB in 2023, with a slight increase of 1.7% [4]. - Net profit is expected to decrease by 3.6% in 2023, followed by a significant recovery of 47.5% in 2025 [4]. - The company’s PE ratio is forecasted to decrease from 18.26 in 2023 to 12.34 in 2026, indicating an improving valuation over time [4]. Pipeline Overview - The company has a leading position in the oncology pipeline, particularly with SYS6010, which is the fastest progressing EGFR ADC globally, with multiple early-stage assets expected to report data in 2026 [10][16]. - In the weight loss and metabolic areas, the company has established a leading position domestically and has signed a strategic collaboration with AstraZeneca for the development of innovative long-acting peptide drugs [10][24]. - The company has a robust pipeline in the small nucleic acid technology sector, positioning it as a leader in the domestic siRNA market [10][24]. Business Development and International Strategy - The company is making steady progress in its international strategy, with ongoing collaborations with AstraZeneca and other multinational corporations, reflecting its competitive edge in innovative drug development [10][24]. - The company is expected to continue achieving external licensing agreements, with over 20 innovative drug assets entering clinical stages annually [10][24].

Core Insights - Hainan Haiyao Co., Ltd. has achieved significant progress in its innovative drug development pipeline, with two new drugs reaching key clinical milestones, enhancing the company's competitive edge in the treatment of neurological and liver diseases [1] Group 1: Drug Development Progress - The drug Paenagabin, developed in collaboration with the Shanghai Institute of Materia Medica, has successfully completed Phase IIa clinical trials, showing promising results in treating focal epilepsy [2] - The Phase II clinical trial of the drug Fluofenidone, developed with Central South University, has met its primary research endpoints, indicating its potential in treating chronic hepatitis B-related liver fibrosis [4] Group 2: Clinical Trial Details - Paenagabin is a new generation KCNQ potassium channel agonist, targeting focal epilepsy that is resistant to existing treatments, with no similar products currently available globally [2][3] - The Phase II trial of Fluofenidone has established optimal dosing for reversing liver fibrosis and improving liver function, with safety profiles comparable to placebo [4][5] Group 3: Market Potential and Future Plans - There is a significant unmet clinical need in epilepsy treatment, with approximately 30% of patients not responding well to current therapies, positioning Paenagabin as a potential solution [3] - Fluofenidone has been recognized as a breakthrough therapy by the National Medical Products Administration, which may expedite its approval process [5] - Hainan Haiyao aims to expand its drug pipeline with a focus on multiple indications and targets, enhancing its research and development efforts to meet clinical demands [6][7]

长江商报消息 ●长江商报记者 李璟 百亿重整完成后，人福医药（600079.SH）再获新控股股东力挺。 2月24日晚间，人福医药发布公告称，公司拟向控股股东招商生命科技（武汉）有限公司（简称"招商生 科"）定向发行股份募资资金30亿元至35亿元，用于创新药研发及制造体系升级。 本次交易构成关联交易，被市场视为新控股股东持续"输血"与战略整合的重要信号。 2025年，万亿级央企招商局集团携118亿元入主，受原股东债务危机影响的人福医药迎来新生。其后， 随着债务重整的顺利推进和新控股股东的增持，为公司未来发展注入强劲动能。2025年前三季度，人福 医药实现归母净利润16.89亿元，同比增长6.22%，盈利能力出现回暖。 加码创新药研发及基地建设 获新控股股东鼎力支持 公开资料显示，人福医药成立于1993年，1997年在上交所挂牌上市。公司核心产品包括枸橼酸舒芬太尼 注射液、注射用盐酸瑞芬太尼等，是资本市场为数不多的精神麻醉药品上市公司。 公告显示，此次定增，人福医药拟向控股股东招商生科发行股票募集资金30亿元至35亿元，扣除相关发 行费用后的募集资金净额拟用于创新药研发项目—子公司宜昌人福项目、创新药研发项目—总 ...